Clinical outcome of management of acute myeloid leukemia with idarubicin plus cytarabine
DOI:
https://doi.org/10.21649/akemu.v11i4.1100Keywords:
Idarubicin. Cytarabine. Leukemia, Myeloid, Acute. Prospective Study. Leukemia, Myeloid. Trisomy. Leukemia. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Chromosomes, Human, Pair 18.Abstract
A prospective study was conducted at Department of Clinical Oncology, King Edward Medical College / Mayo Hospital, Lahore from July 2003 to June 2004 to evaluate the effect of Idarubicin plus Cytarabine in chemo naive Acute Myeloid Leukemia (AML) patients. A total of 15 consecutive patients were enrolled with age group 15-58 years. Patients were classified according to French American British (FAB) classification. Induction therapy with Cytarabine as continuous infusion for 7 days and Idarubicin was given on day 1-3. For assessment of response, all patients were subjected to bone marrow examination fifteen days after completion of Induction chemotherapy. Consolidation Therapy with high dose Cytarabine was given on days 1, 3 and 5. Cytarabine was repeated after 28 days for 4 cycles in patients with complete remission after induction therapy. A remission induction rate of 66.7% was observed. Four patients died because of complications. One patient lost to follow up. Idarubicine and cytarabine is effective r egimen for achieving complete remission in AML Chemo-naive patients.
Published
How to Cite
Issue
Section
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments publications@kemu.edu.pk
